BioCentury
ARTICLE | Clinical News

Actelion reports Phase II CDAD data

December 22, 2012 1:33 AM UTC

Actelion Ltd. (SIX:ATLN) said three doses of twice-daily oral cadazolid each produced "numerically similar" clinical cure rates, the primary endpoint, vs. oral vancomycin given four times daily in a P...